{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:17:56Z","timestamp":1791299876255,"version":"4.1.0"},"reference-count":121,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL114800"],"award-info":[{"award-number":["R01 HL114800"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1080\/13543784.2023.2249399","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:55:03Z","timestamp":1692953703000},"page":"693-704","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome"],"prefix":"10.1080","volume":"32","author":[{"given":"Katrina","family":"Kuhn","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Lederman","sequence":"additional","affiliation":[{"name":"Eudowood Division of Pediatric, Allergy and Immunology, Johns Hopkins School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"McGrath-Morrow","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia Division of Pulmonary Medicine and Sleep and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0543-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.094268"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06723-z"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.64.02.148"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13618"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02940"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-021-01257-4"},{"key":"e_1_3_4_10_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejpn.2021.04.002","article-title":"Neurofilament light chain: a novel blood biomarker in patients with ataxia telangiectasia","volume":"32","author":"Veenhuis SJG","year":"2021","unstructured":"Veenhuis SJG, Gupta AS, de Gusm\u00e3o CM, et al. Neurofilament light chain: a novel blood biomarker in patients with ataxia telangiectasia. Eur J Paediatr Neurol. 2021 May;32:93\u201397.","journal-title":"Eur J Paediatr Neurol"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01090-8"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpeds.2016.01.002","article-title":"Serum interleukin-6 levels and pulmonary function in ataxia-telangiectasia","volume":"171","author":"McGrath-Morrow SA","year":"2016","unstructured":"McGrath-Morrow SA, Collaco JM, Detrick B, et al. Serum interleukin-6 levels and pulmonary function in ataxia-telangiectasia. J Pediatr. 2016 [2016 Feb2];171:256\u2013261.e1.","journal-title":"J Pediatr"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23240"},{"issue":"14","key":"e_1_3_4_14_1","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens MA","year":"2016","unstructured":"Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016 Aug 19;44(14):6549\u20136563.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"e_1_3_4_15_1","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1073\/pnas.0608616104","article-title":"Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides","volume":"104","author":"Du L","year":"2007","unstructured":"Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6007\u20136012.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21632"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2012.266"},{"issue":"16","key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/hmg\/ddr217","article-title":"Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum","volume":"20","author":"Du L","year":"2011","unstructured":"Du L, Kayali R, Bertoni C, et al. Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet. 2011 Aug 15;20(16):3151\u20133160.","journal-title":"Hum Mol Genet"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1364159"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.664710"},{"issue":"5","key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry E","year":"2019","unstructured":"Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019 Mar 6;101(5):839\u2013862.","journal-title":"Neuron"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01664-4"},{"issue":"5","key":"e_1_3_4_23_1","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1093\/nar\/gkac104","article-title":"Persistent DNA damage associated with ATM kinase deficiency promotes microglial dysfunction","volume":"50","author":"Bourseguin J","year":"2022","unstructured":"Bourseguin J, Cheng W, Talbot E, et al. Persistent DNA damage associated with ATM kinase deficiency promotes microglial dysfunction. Nucleic Acids Res. 2022 Mar 21;50(5):2700\u20132718.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13468"},{"issue":"1","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1074\/jbc.M106798200","article-title":"Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of atm-deficient mice","volume":"277","author":"Stern N","year":"2002","unstructured":"Stern N, Hochman A, Zemach N, et al. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of atm-deficient mice. J Biol Chem. 2002 Jan 4;277(1):602\u2013608.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-011-9643-y"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192912"},{"issue":"20","key":"e_1_3_4_28_1","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2012-09-456897","article-title":"Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions","volume":"121","author":"Ambrose M","year":"2013","unstructured":"Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013 May 16;121(20):4036\u20134045.","journal-title":"Blood"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S35759"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.redox.2016.12.030","article-title":"Oxidative stress, mitochondrial abnormalities and antioxidant defense in ataxia-telangiectasia, bloom syndrome and Nijmegen breakage syndrome","volume":"11","author":"Maciejczyk M","year":"2017","unstructured":"Maciejczyk M, Mikoluc B, Pietrucha B, et al. Oxidative stress, mitochondrial abnormalities and antioxidant defense in ataxia-telangiectasia, bloom syndrome and Nijmegen breakage syndrome. Redox Biol. 2017 Apr;11:375\u2013383.","journal-title":"Redox Biol"},{"key":"e_1_3_4_31_1","first-page":"285","article-title":"The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress","volume":"29","author":"Rotman G","year":"1997","unstructured":"Rotman G, Shiloh Y. The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surv. 1997;29:285\u2013304.","journal-title":"Cancer Surv"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(96)00336-X"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.350194"},{"issue":"17","key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1073\/pnas.96.17.9915","article-title":"Loss of the ataxia\u2013telangiectasia gene product causes oxidative damage in target organs","volume":"96","author":"Barlow C","year":"1999","unstructured":"Barlow C, Dennery PA, Shigenaga MK, et al. Loss of the ataxia\u2013telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci USA. 1999 Aug 17;96(17):9915\u20139919.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1005"},{"issue":"5","key":"e_1_3_4_36_1","first-page":"1849","article-title":"Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from atm-deficient mice","volume":"61","author":"Kamsler A","year":"2001","unstructured":"Kamsler A, Daily D, Hochman A, et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from atm-deficient mice. Cancer Res. 2001 Mar 1;61(5):1849\u20131854.","journal-title":"Cancer Res"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13329"},{"issue":"36","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"11453","DOI":"10.1523\/JNEUROSCI.23-36-11453.2003","article-title":"Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxia-telangiectasia mutated mutant mice","volume":"23","author":"Chen P","year":"2003","unstructured":"Chen P, Peng C, Luff J, et al. Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxia-telangiectasia mutated mutant mice. J Neurosci. 2003 Dec 10;23(36):11453\u201311460.","journal-title":"J Neurosci"},{"issue":"7","key":"e_1_3_4_39_1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.freeradbiomed.2004.01.003","article-title":"Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice","volume":"36","author":"Browne SE","year":"2004","unstructured":"Browne SE, Roberts LJ 2nd, Dennery PA, et al. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med. 2004 Apr 1;36(7):938\u2013942.","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1158\/0008-5472.CAN-04-0442","article-title":"Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice","volume":"64","author":"Reliene R","year":"2004","unstructured":"Reliene R, Fischer E, Schiestl RH. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 2004 Aug 1;64(15):5148\u20135153.","journal-title":"Cancer Res"},{"issue":"7","key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.dnarep.2006.05.003","article-title":"Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in atm deficient mice","volume":"5","author":"Reliene R","year":"2006","unstructured":"Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in atm deficient mice. DNA Repair (Amst). 2006 Jul 13;5(7):852\u2013859.","journal-title":"DNA Repair (Amst)"},{"issue":"4","key":"e_1_3_4_42_1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.cmet.2016.09.004","article-title":"NAD(+) replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair","volume":"24","author":"Fang EF","year":"2016","unstructured":"Fang EF, Kassahun H, Croteau DL, et al. NAD(+) replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 2016 Oct 11;24(4):566\u2013581.","journal-title":"Cell Metab"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28788"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1959-9404"},{"issue":"6","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2011-08-373639","article-title":"Mitochondrial dysfunction in ataxia-telangiectasia","volume":"119","author":"Valentin-Vega YA","year":"2012","unstructured":"Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012 Feb 9;119(6):1490\u20131500.","journal-title":"Blood"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8850708"},{"key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.molmet.2021.101354","article-title":"An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T)","volume":"54","author":"Yeo AJ","year":"2021","unstructured":"Yeo AJ, Subramanian GN, Chong KL, et al. An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T). Mol Metab. 2021 Dec;54:101354.","journal-title":"Mol Metab"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085863"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4VMA0716-316R"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1479"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02060.x"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02600.x"},{"issue":"10","key":"e_1_3_4_53_1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mds.25126","article-title":"A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia","volume":"27","author":"Zannolli R","year":"2012","unstructured":"Zannolli R, Buoni S, Betti G, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord. 2012 Sep 1;27(10):1312\u20131316.","journal-title":"Mov Disord"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03203.x"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2012.06.002"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13606"},{"key":"e_1_3_4_57_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2019.05.006","article-title":"Long-term evaluation of low-dose betamethasone for ataxia telangiectasia","volume":"100","author":"Hasegawa S","year":"2019","unstructured":"Hasegawa S, Kumada S, Tanuma N, et al. Long-term evaluation of low-dose betamethasone for ataxia telangiectasia. Pediatr Neurol. 2019 Nov;100:60\u201366.","journal-title":"Pediatr Neurol"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5895"},{"issue":"1","key":"e_1_3_4_59_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2016.12.011","article-title":"Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment","volume":"517","author":"Mambrini G","year":"2017","unstructured":"Mambrini G, Mandolini M, Rossi L, et al. Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment. Int J Pharm. 2017 Jan 30;517(1\u20132):175\u2013184.","journal-title":"Int J Pharm"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2017.09.001"},{"issue":"1","key":"e_1_3_4_61_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-9-5","article-title":"Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial","volume":"9","author":"Chessa L","year":"2014","unstructured":"Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis. 2014 Jan 9;9(1):5.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000098"},{"issue":"1","key":"e_1_3_4_63_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13023-017-0669-2","article-title":"ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T","volume":"12","author":"Menotta M","year":"2017","unstructured":"Menotta M, Biagiotti S, Spapperi C, et al. ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T. Orphanet J Rare Dis. 2017 Jul 5;12(1):126.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"20182","DOI":"10.1038\/s41598-020-77352-z","article-title":"In vitro dexamethasone treatment does not induce alternative ATM transcripts in cells from ataxia-telangiectasia patients","volume":"10","author":"Pozzi E","year":"2020","unstructured":"Pozzi E, Giorgio E, Mancini C, et al. In vitro dexamethasone treatment does not induce alternative ATM transcripts in cells from ataxia-telangiectasia patients. Sci Rep. 2020 Nov 19;10(1):20182.","journal-title":"Sci Rep"},{"key":"e_1_3_4_65_1","volume-title":"American Academy of Neurology 2022 Annual Meeting","author":"Zielen S","year":"2022","unstructured":"Zielen S, Whitehouse W, Magnani M, et al. The pivotal multi-center, randomized, double-blind, placebo-controlled trial of intra-erythrocyte dexamethasone sodium phosphate (ATTeST) on the neurological motor function of people with ataxia telangiectasia. American Academy of Neurology 2022 Annual Meeting; 2022 Apr 5; Seattle, Washington, USA; 2022."},{"issue":"1","key":"e_1_3_4_66_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-018-0880-9","article-title":"Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials","volume":"13","author":"Cortina-Borja M","year":"2018","unstructured":"Cortina-Borja M, Te Vruchte D, Mengel E, et al. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet J Rare Dis. 2018 Aug 16;13(1):143.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738211028394"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-022-01371-x"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-05009-3"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-019-04399-3"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073812441999"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12048"},{"issue":"13","key":"e_1_3_4_73_1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1212\/WNL.0b013e3182a55fa2","article-title":"Ataxia telangiectasia presenting as dopa-responsive cervical dystonia","volume":"81","author":"Charlesworth G","year":"2013","unstructured":"Charlesworth G, Mohire MD, Schneider SA, et al. Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology. 2013 Sep 24;81(13):1148\u20131151.","journal-title":"Neurology"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2020.03.019"},{"issue":"3","key":"e_1_3_4_75_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1388-1981(99)00022-0","article-title":"Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia","volume":"1437","author":"Yorek MA","year":"1999","unstructured":"Yorek MA, Dunlap JA, Manzo-Fontes A, et al. Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia. Biochim Biophys Acta. 1999 Mar 25;1437(3):287\u2013300.","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldm012"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7046-4"},{"issue":"2","key":"e_1_3_4_78_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","article-title":"Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies","volume":"33","author":"Suarez F","year":"2015","unstructured":"Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol. 2015 Jan 10;33(2):202\u2013208.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17736"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011811-132509"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019509029550"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200201000-00021"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2016.05.012"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001005"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04041_4.x"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21808"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182804d59"},{"issue":"2","key":"e_1_3_4_88_1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/ijms24021099","article-title":"Successful treatment of large B-Cell lymphoma in a child with compound heterozygous mutation in the ATM gene","volume":"24","author":"Czarny J","year":"2023","unstructured":"Czarny J, Andrzejewska M, Zaj\u0105c-Spycha\u0142a O, et al. Successful treatment of large B-Cell lymphoma in a child with compound heterozygous mutation in the ATM gene. Int J Mol Sci. 2023 Jan 6;24(2):1099.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20548"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25621"},{"issue":"2","key":"e_1_3_4_91_1","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1097\/MPH.0000000000002250","article-title":"Pediatric EBV positive mucocutaneous ulceration in stomach a rare entity","volume":"44","author":"Alakaya M","year":"2022","unstructured":"Alakaya M, Gundogan BD, Arslankoylu AE, et al. Pediatric EBV positive mucocutaneous ulceration in stomach a rare entity. J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e503\u2013e506.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"e_1_3_4_92_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/hmg\/dds448","article-title":"Bone marrow transplantation improves the outcome of atm-deficient mice through the migration of ATM-competent cells","volume":"22","author":"Pietzner J","year":"2013","unstructured":"Pietzner J, Baer PC, Duecker RP, et al. Bone marrow transplantation improves the outcome of atm-deficient mice through the migration of ATM-competent cells. Hum Mol Genet. 2013 Feb 1;22(3):493\u2013507.","journal-title":"Hum Mol Genet"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02785"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693897"},{"issue":"16","key":"e_1_3_4_95_1","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2016-09-743112","article-title":"Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study","volume":"129","author":"Mehta PA","year":"2017","unstructured":"Mehta PA, Davies SM, Leemhuis T, et al. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017 Apr 20;129(16):2308\u20132315.","journal-title":"Blood"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02495"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9654-7"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.207"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.93"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.001"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.12.001"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20209"},{"issue":"3","key":"e_1_3_4_103_1","first-page":"1046","article-title":"Unusual sensitivity of ataxia telangiectasia cells to bleomycin","volume":"39","author":"Taylor AM","year":"1979","unstructured":"Taylor AM, Rosney CM, Campbell JB. Unusual sensitivity of ataxia telangiectasia cells to bleomycin. Cancer Res. 1979 Mar;39(3):1046\u20131050.","journal-title":"Cancer Res"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200001)34:1<65:AID-MPO15>3.0.CO;2-8"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13037"},{"issue":"6","key":"e_1_3_4_106_1","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1074\/jbc.M410344200","article-title":"Full activation of PKB\/Akt in response to insulin or ionizing radiation is mediated through ATM","volume":"280","author":"Viniegra JG","year":"2005","unstructured":"Viniegra JG, Mart\u00ednez N, Modirassari P, et al. Full activation of PKB\/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005 Feb 11;280(6):4029\u20134036.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/35046542"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00317"},{"issue":"2","key":"e_1_3_4_109_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng.735","article-title":"Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes","volume":"43","author":"Zhou K","year":"2011","unstructured":"Zhou K, Bellenguez C, Spencer CC, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genet. 2011 Feb;43(2):117\u2013120.","journal-title":"Nature Genet"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.3109\/08977194.2014.939805"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/08977194.2017.1367681"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0581-0"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06619.x"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02000"},{"issue":"8","key":"e_1_3_4_115_1","first-page":"608","article-title":"Cutaneous granulomatous lesions disclosing ataxia-telangiectasia","volume":"126","author":"Corbisier A","year":"1999","unstructured":"Corbisier A, Eschard C, Motte J, et al. Cutaneous granulomatous lesions disclosing ataxia-telangiectasia. Ann Dermatol Venereol. 1999 Aug;126(8\u20139):608\u2013611.","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83043-4"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12411"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15032"},{"issue":"3","key":"e_1_3_4_119_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/pathogens11030338","article-title":"Drug sensitivity of vaccine-derived rubella viruses and quasispecies evolution in granulomatous lesions of two ataxia-telangiectasia patients treated with nitazoxanide","volume":"11","author":"Faisthalab R","year":"2022","unstructured":"Faisthalab R, Suppiah S, Dorsey M, et al. Drug sensitivity of vaccine-derived rubella viruses and quasispecies evolution in granulomatous lesions of two ataxia-telangiectasia patients treated with nitazoxanide. Pathogens. 2022 Mar 11;11(3):338.","journal-title":"Pathogens"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.060"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00390"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886540"},{"issue":"1","key":"e_1_3_4_123_1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12974-018-1338-7","article-title":"Ibuprofen prevents progression of ataxia telangiectasia symptoms in ATM-deficient mice","volume":"15","author":"Hui CW","year":"2018","unstructured":"Hui CW, Song X, Ma F, et al. Ibuprofen prevents progression of ataxia telangiectasia symptoms in ATM-deficient mice. J Neuroinflammation. 2018 Nov 6;15(1):308.","journal-title":"J Neuroinflammation"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2249399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:09:31Z","timestamp":1695316171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2249399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["10.1080\/13543784.2023.2249399"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2249399","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}